Next, we explored whether transcriptomics can further expand the molecular classification of HLBCs, by comparing the gene expression profiles (GEPs) of 91 HLBCs with control cohorts of 30 HER2-negative and 15 HER2-positive carcinomas. The gene discussed is ERBB2; the disease is carcinoma.